Surgical devices maker Misonix (NSDQ:MSON) took some hits during the 3 months ended Dec. 31, 2012, with an unfavorable product mix swinging the company into the red.

The company reported losses of about $654,000, or -9¢ per share, during the 2nd quarter, a hard swing from profits of $1 million, or 15¢ per diluted share, during the same period in 2011. The Q2 earnings missed analysts’ expectations by 3¢.

"Bottom-line results were impacted by an unfavorable product mix of low and high margin product deliveries, additional headcount as we continue to invest in our sales and marketing team, and increased selling expenses as more distributors become engaged in selling our products," president & CEO Michael McManus Jr. said in prepared remarks. "We expect that these impacts will be offset as we continue to grow revenues in the coming quarters."

Misonix hired 23 independent neurospine representatives and 10 wound care reps during the quarter. Total operating costs increased 16.5% to $3 million.

Royalty income from a deal with medical device giant Covidien (NYSE:COV) increased 177% to $502,000.

Farmingdale, N.Y.-based Misonix reported $3.5 million in sales during the quarter, a 2.2% decrease from the $3.6 million reported during the same period in 2011.

U.S. took a 12.6% hit during the 3 months ended Dec. 31, 2012, including a 59% decrease in LySonix and AutoSonix sales. Non-U.S. sales rose by 9.6% compared with the same period in the previous year.

Certain of the company’s products fared well during the quarter. Revenues related to the BoneScalpel bone cutting and shaving system, SonicOne wound debridement system and SonaStar surgical aspirator system increased 12%, according to the financial report.

MSON shares have dropped hard since the company released its financial report. Trading opened at $7.78 on February 4, prior to the earnings release, and had lost 7% to close at $7.23 at the end of the day. Shares have lost another 23% since then, and were trading at $5.60 as of about 1:10 p.m. today.